Back to top
more

LeMaitre Vascular (LMAT)

(Delayed Data from NSDQ)

$91.73 USD

91.73
102,201

+0.97 (1.07%)

Updated Oct 4, 2024 03:59 PM ET

After-Market: $91.67 -0.06 (-0.07%) 4:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 20% (49 out of 251)

Industry: Medical - Products

Better trading starts here.

Zacks News

LeMaitre Vascular (LMAT) Earnings Expected to Grow: Should You Buy?

LeMaitre (LMAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Edwards Lifesciences (EW) Beats on Q1 Earnings, Margins Down

Despite coronavirus-led business challenges, Edwards Lifesciences (EW) witnessed robust segmental performances in Q1.

Thermo Fisher (TMO) Gets EUA for Amplitude/TaqPath COVID-19 Kit

Thermo Fisher's (TMO) Amplitude Solution is likely to allow clinical and public health laboratories to process up to 8,000 samples in a single day with the help of minimum workforce.

Thermo Fisher (TMO) Rides on End Markets as Pandemic Rages On

In diagnostics and healthcare, Thermo Fisher (TMO) is experiencing high demand for COVID-19 testing and manages to record 200% growth.

Medtronic's (MDT) GI Genius Module Gets FDA De Novo Clearance

Medtronic's (MDT) GI Genius Module is the only commercially available computer-aided detection system which uses artificial intelligence to identify colorectal polyploid.

Debanjana Dey headshot

4 Critical Care Device Stocks to Deflect the COVID-19 Curveball

Cantel (CMD), Hill-Rom (HRC), LeMaitre (LMAT) and Masimo (MASI) can prove to be prudent investment choices in the critical care industry of the MedTech sector.

New Strong Buy Stocks for April 8th

MDC, NTR, LMAT, CSTR, and MYRG have been added to the Zacks Rank #1 (Strong Buy) List on April 8, 2021.

Debanjana Dey headshot

5 MedTech Growth Stocks Gaining Ground in 2021 Amid Pandemic

Here are a few MedTech stocks, ABT, HOLX, HRC, IDXX, LMAT, which have held their ground amid the pandemic and can turn out to be wise investment choices for 2021.

Is LeMaitre (LMAT) a Solid Growth Stock? 3 Reasons to Think " Yes "

LeMaitre (LMAT) possesses solid growth attributes, which could help it handily outperform the market.

LeMaitre (LMAT) Stock Jumps 5.2%: Will It Continue to Soar?

LeMaitre (LMAT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Agios (AGIO) to Sell Oncology Drugs to Servier for $2B, Stock Up

Agios (AGIO) sells its oncology business unit to French company Servier for around $2 billion. The company plans to solely focus on developing treatments for genetically defined diseases. Shares rise.

Zacks.com featured highlights include: Winnebago, Shutterstock, Ituran Location and Control, LeMaitre Vascular and Logitech

Zacks.com featured highlights include: Winnebago, Shutterstock, Ituran Location and Control, LeMaitre Vascular and Logitech

Radhika Pujara headshot

5 Top-Ranked Liquid Stocks To Bet On For Alluring Returns

Here are five top-ranked liquid stocks, Winnebago Industries, (WGO), Shutterstock (SSTK), Logitech (LOGI), Ituran Location and Control (ITRN), and LeMaitre Vascular (LMAT), that investors can snap up for a winning portfolio.

Agios' (AGIO) Phase III Study on Mitapivat Meets Primary Goal

Agios' (AGIO) phase III ACTIVATE study evaluating mitapivat for addressing PK deficiency in patients with no regular blood transfusions achieves the primary goal.

Zacks.com featured highlights include: Shutterstock, Winnebago Industries, LeMaitre and Logitech

Zacks.com featured highlights include: Shutterstock, Winnebago Industries, LeMaitre and Logitech

Radhika Pujara headshot

4 Promising Top-Ranked Liquid Stocks to Boost Your Portfolio

Here are four top-ranked liquid stocks, Winnebago Industries (WGO), Shutterstock (SSTK), Logitech (LOGI), and LeMaitre Vascular (LMAT), that investors can snap up for a winning portfolio.

3 Reasons Why Growth Investors Shouldn't Overlook LeMaitre (LMAT)

LeMaitre (LMAT) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Agios' (AGIO) Mitapivat Gets Orphan Drug Tag to Treat SCD

The FDA confers an orphan drug status on Agios' (AGIO) pyruvate kinase-R activator mitapivat for addressing sickle cell disease. Stock climbs in after-hours trading.

Boston Scientific (BSX) in Focus: Stock Moves 7% Higher

Boston Scientific (BSX) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

LeMaitre Vascular (LMAT) Q3 Earnings and Revenues Top Estimates

LeMaitre (LMAT) delivered earnings and revenue surprises of 76.19% and 13.11%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate LeMaitre Vascular (LMAT) to Report a Decline in Earnings: What to Look Out for

LeMaitre (LMAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Moving Average Crossover Alert: LeMaitre Vascular

LeMaitre Vascular is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

LeMaitre Vascular (LMAT) Tops Q2 Earnings and Revenue Estimates

LeMaitre (LMAT) delivered earnings and revenue surprises of 440.00% and 59.48%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: LeMaitre Vascular (LMAT) Q2 Earnings Expected to Decline

LeMaitre (LMAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ritujay Ghosh headshot

Trump Pushes for US-Made Medical Products: 4 Winners

An executive order to address the lack of medical product manufacturing in the United States could in a way boost manufacturing and sales of home-grown goods.